TARGET GENE
GALC
TARGET ENZYME
Galactosylceramidase
PRIMARY
STORAGE
Galactosylsphingosine
SECONDARY
STORAGE
Alpha-synuclein
EPIDEMIOLOGY
1 : 100-250,000
UNMET MEDICAL NEED
No available treatment or cure
DEVELOPMENT
STAGE
Discovery
In vitro
Meet us at
BIO-Europe Spring on March 25 - 27, 2019 in Vienna, Austria.
Gain Therapeutics SA has been selected to present on March 26th, 2019.
March 8, 2019
Gain Therapeutics SA
announces that it has received funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA to advance its proprietary non-competitive pharmacological chaperones for Parkinson’s disease.
February 26, 2019
Rare Disease Day 2018
​
Wednesday, February 28
​
View link to events worldwide:
https://www.rarediseaseday.org/
February 14, 2018
Gain Therapeutics, a new company
​
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics
February 20, 2018
GT Gain Therapeutics SA
announces that it has closed a €2.5 Million series A financing to develop novel brain-penetrant non-competitive pharmacological chaperones for rare lysosomal storage diseases and CNS indications.
February 19, 2019
